551 related articles for article (PubMed ID: 35289434)
1. Advances in the Omicron variant development.
Vitiello A; Ferrara F; Auti AM; Di Domenico M; Boccellino M
J Intern Med; 2022 Jul; 292(1):81-90. PubMed ID: 35289434
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
5. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
[TBL] [Abstract][Full Text] [Related]
6. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
[TBL] [Abstract][Full Text] [Related]
7. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y
Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809
[TBL] [Abstract][Full Text] [Related]
8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
10. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
[TBL] [Abstract][Full Text] [Related]
11. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
[TBL] [Abstract][Full Text] [Related]
12. Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.
Tiecco G; Storti S; Degli Antoni M; Focà E; Castelli F; Quiros-Roldan E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216104
[TBL] [Abstract][Full Text] [Related]
13. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
[TBL] [Abstract][Full Text] [Related]
14. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
15. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
[TBL] [Abstract][Full Text] [Related]
16. Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein.
Khan SA; Khan A; Zia K; Shawish I; Barakat A; Ul-Haq Z
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142242
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
18. Omicron variant evolution on vaccines and monoclonal antibodies.
Sabbatucci M; Vitiello A; Clemente S; Zovi A; Boccellino M; Ferrara F; Cimmino C; Langella R; Ponzo A; Stefanelli P; Rezza G
Inflammopharmacology; 2023 Aug; 31(4):1779-1788. PubMed ID: 37204696
[TBL] [Abstract][Full Text] [Related]
19. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
20. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
